Efficacy relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy

被引：0

作者：

Ying Zhou

Jinmei Zhou

Xiaopeng Hao

Haoyuan Shi

Xuejie Li

Anqi Wang

Zhiyuan Hu

Yanlian Yang

Zefei Jiang

Tao Wang

机构：

[1] Fujian Medical University,Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, School of Basic Medical Sciences

[2] CAS Center for Excellence in Nanoscience,CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety

[3] National Center for Nanoscience and Technology of China,Breast Cancer Department

[4] The Fifth Medical Center of Chinese PLA General Hospital,Department of General Surgery

[5] The Fifth Medical Center of Chinese PLA General Hospital,School of Nanoscience and Technology

[6] Sino-Danish College,School of Chemical Engineering and Pharmacy

[7] University of Chinese Academy of Sciences,undefined

[8] Wuhan Institute of Technology,undefined

[9] Anhui Medical University,undefined

[10] Southern Medical University,undefined

来源：

Breast Cancer Research and Treatment | 2023年 / 200卷

关键词：

Circulating tumor cells; Breast cancer; Programmed death-ligand 1; Programmed death-1; Immunotherapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：281 / 291

页数：10

共 50 条

[1] Efficacy relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy
Zhou, Ying
Zhou, Jinmei
Hao, Xiaopeng
Shi, Haoyuan
Li, Xuejie
Wang, Anqi
Hu, Zhiyuan
Yang, Yanlian
Jiang, Zefei
Wang, Tao
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2023, 200 (02) : 281 - 291
[2] Prognostic relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy
Zhou, Ying
Zhou, Jinmei
Shi, Haoyuan
Hu, Zhiyuan
Yang, Yanlian
Jiang, Zefei
Wang, Tao
[J]. CANCER RESEARCH, 2023, 83 (05)
[3] PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer
Darga, Elizabeth P.
Dolce, Emily M.
Fang, Fang
Kidwell, Kelley M.
Gersch, Christina L.
Kregel, Steven
Thomas, Dafydd G.
Gill, Anoop
Brown, Martha E.
Gross, Steven
Connelly, Mark
Holinstat, Michael
Cobain, Erin F.
Rae, James M.
Hayes, Daniel F.
Paoletti, Costanza
[J]. PLOS ONE, 2021, 16 (11):
[4] Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence
Qi, Yihang
Zhang, Lin
Wang, Zhongzhao
Kong, Xiangyi
Zhai, Jie
Fang, Yi
Wang, Jing
[J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
[5] Targeting regulatory T cells in anti-PD-1/PD-L1 cancer immunotherapy
Zhulai, Galina
Oleinik, Eugenia
[J]. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2022, 95 (03)
[6] PD-L1 expression by circulating breast cancer cells
David, Rachel
[J]. LANCET ONCOLOGY, 2015, 16 (07): : E321 - E321
[7] Is anti-PD-1/PD-L1 immunotherapy sensitizing for conventional cancer therapies?
Matias, M.
Aspeslagh, S.
Palomar, V.
Lanoy, E.
Dercle, L.
Even, C.
Ferte, C.
Hollebecque, A.
Marabelle, A.
Massard, C.
Soria, J-C.
Postel-Vinay, S.
[J]. ANNALS OF ONCOLOGY, 2016, 27
[8] PD-L1 expression on circulating tumor cells and prognosis of breast cancer patients.
Wang, Xuefei
Zhang, Goechao
Sun, Qiang
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[9] Assessment of PD-L1 expression in circulating tumor cells in patients with breast cancer.
Chen, Junqing
Chen, Zhanhong
Wang, Xiaojia
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[10] Monitoring PD-L1 expression on circulating stromal cells in blood predicts PFS and OS in patients with metastatic NSCLC treated with PD-L1/PD-1 immunotherapy.
Moran, Jillian
Adams, Daniel L.
Bravo, Pablo Lopez
He, Jianzhong
Qiao, Yawei
Xu, Ting
Liao, Zhongxing X.
Gardner, Kirby P.
Tang, Cha-Mei
Lin, Steven H.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →